PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|November 12, 2014
Essentra to Acquire Clondalkin's Specialist Packaging Division
Author(s)Pharmaceutical Technology Editors
Essentra has signed an agreement to acquire Clondalkin's Specialist Packaging Division for a cash consideration of approximately $455 million.
Advertisement
Essentra has signed an agreement to acquire Clondalkin’s Specialist Packaging Division for a cash consideration of approximately $455 million. According to the press release, the transaction marks Essentra’s largest acquisition to date and is expected to complete in the first quarter of 2015.
Clondalkin SPD is a global provider of speciality secondary packaging solutions for the pharmaceutical and health and personal care industries, with 24 facilities. It is believed that the acquisition will add to Essentra’s position in these markets.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
Complying with International Pharmacopoeias
4
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
5